Skip to main
  1. Stocks
  2. Ionis Pharma
  3. Forecast
IONS

Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharma (IONS) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Ionis Pharmaceuticals is attractive because its antisense platform has already produced multiple approved drugs, including Spinraza, Qalsody, Wainua, Tryngolza, Dawnzera, Tegsedi, and Waylivra, validating both the science and its ability to convert R&D into recurring royalty and product revenue. The company also has a broad wholly owned and partnered pipeline in cardiometabolic, neurological, and rare diseases, with several positive readouts expected in FY27 and additional partnered programs like Hibsago, sefaxersen, and ulefnersen that can add milestone and royalty upside. Commercial momentum looks underappreciated: Dawnzera generated $37M in Q3 sales, Spinraza royalties reached $69M versus $55M consensus, and Tryngolza still carries blockbuster potential despite a moderate launch, supporting a favorable long-term fundamental view.

Bears say

Ionis Pharmaceuticals is facing a weaker fundamental setup because Tryngolza’s launch is materially underperforming, with Q3 sales of about $9M versus $20M-$21M expected and management cutting FY26 guidance to roughly $50M from $100M-$110M, while only about 1,500 HCPs have prescribed and just 24% have written more than one script. The slow ramp reflects limited formulary coverage, heavy reliance on free drug through Quick Start, step-edit barriers, and cautious physician adoption, which together push the path to broader monetization and the >$3B peak-sales narrative much further out. At the same time, Wainua royalties are moderating, obudanersen’s probability of success was cut to 35% after ASPIRE, and cash-flow break-even has been pushed to 2029, increasing execution and financing risk despite a still-strong $1.884B cash balance.

Ionis Pharma (IONS) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ionis Pharma and is not a guaranteed prediction by Public.com or investment advice.

Ionis Pharma (IONS) Analyst Forecast & Price Prediction

Get the latest Ionis Pharma (IONS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ionis Pharma (IONS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ionis Pharma (IONS) Forecast

Analysts have given Ionis Pharma (IONS) a Buy based on their latest research and market trends.

According to 20 analysts, Ionis Pharma (IONS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ionis Pharma (IONS)


Ionis Pharma (IONS) Analyst Forecast & Price Prediction

Get the latest Ionis Pharma (IONS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ionis Pharma (IONS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IONS stock data and trends